Observational studyInternational urogynecology journal2026
PANTHERA "Pelvic Floor Disorders in Patients Under ANtineoplastic THERApy" Prospective Evaluation of Subjectively Perceived Pelvic Floor Function in Patients with Gynecologic and Breast Cancers Undergoing Systemic Antineoplastic Therapy Using a Validated Pelvic Floor Questionnaire.
Observational study in International urogynecology journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introduction and hypothesisWith increasing cancer survival rates, long-term sequelae of oncological therapies on the pelvic floor-including bladder, bowel, sexual dysfunction, and pelvic organ prolapse-have gained clinical relevance. The PANTHERA study evaluates the impact of systemic antineoplastic therapy on pelvic floor function (PFF) in women with breast and gynecological malignancies.
methodsThis prospective observational study enrolled 201 patients with histologically confirmed breast or gynecological cancers undergoing systemic therapy. PFF was assessed using the validated German Pelvic Floor Questionnaire (GPFQ) before therapy initiation, at treatment completion, and during follow-up. The primary endpoint was the occurrence of a clinically relevant deterioration in overall PFF. Additional data on treatment type and risk factors were collected.
resultsAlmost all patients (99%) received chemotherapy; 33% received endocrine therapy. Breast cancer affected 66% and gynecological cancers 34% of patients. Psychiatric comorbidity and the presence of gynecological malignancy were independently associated with higher baseline pelvic floor dysfunction scores. Mean follow-up time was 3 years (SD 1.8). Importantly, the total GPFQ score showed sustained deterioration across all follow-up intervals. Patients with gynecological cancers had greater baseline impairment but less pronounced therapy-related decline compared with breast cancer patients. Except for prolapse scores, which improved after an initial decline, bladder, bowel, and sexual function worsened persistently over time.
conclusionPelvic floor disorder is a prevalent, impactful, yet underestimated issue in patients undergoing systemic therapy for breast and gynecological cancers. Incorporating structured PFF assessment into routine oncological care is essential to improve long-term quality of life.
Indexed as
Identifiers
41686255What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.